Avanir Pharmaceuticals, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Avanir Pharmaceuticals, Inc..The latest application filed is for "pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depresson, anxiety, and neurodegenerative disorders".

Company Profile

20.6.43

Avanir Pharmaceuticals, Inc. - Aliso Viejo CA US
AVANIR PHARMACEUTICALS, INC. - Aliso Viego CA US
AVANIR PHARMACEUTICALS, INC. -
Avanir Pharmaceuticals, Inc. - Alison Viejo CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Depresson, Anxiety, And Neurodegenerative Disorders App 20220105088 - BERG; James	2022-04-07
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Agitation In Dementia App 20220105084 - SIFFERT; Joao ; et al.	2022-04-07
Methods Of Treating Negative Symptoms Of Schizophrenia Using Deuterated Dextromethorphan And Quinidine App 20220071989 - DUBE; Sanjay	2022-03-10
Methods For The Synthesis Of Deuterated Dextromethorphan App 20210061765 - Johnson; Matt ; et al.	2021-03-04
Enhancement Of Impaired Motor And Mental Functions, Using Dextromethorphan And Oxidase Enzyme Inhibitor App 20210008058 - SMITH; Richard A.	2021-01-14
Methods for the synthesis of deuterated dextromethorphan Grant 10,865,187 - Johnson , et al. December 15, 2	2020-12-15
Enhancement Of Impaired Motor And Mental Functions, Using Dextromethorphan And Oxidase Enzyme Inhibitor App 20200375981 - SMITH; Richard A.	2020-12-03
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Depression, Anxiety, And Neurodegenerative Disorders App 20200368225 - BERG; James	2020-11-26
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Agitation In Dementia App 20200352933 - SIFFERT; Joao ; et al.	2020-11-12
Methods For The Synthesis Of Deuterated Dextromethorphan App 20200317618 - Johnson; Matt ; et al.	2020-10-08
Pharmaceutical Compositions Comprising A Dextromethorphan Compound And Quinidine For The Treatment Of Agitation In Dementia App 20200289499 - SIFFERT; Joao	2020-09-17
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20200276185 - Yakatan; Gerald ; et al.	2020-09-03
Methods for the synthesis of deuterated dextromethorphan Grant 10,730,841 - Johnson , et al.	2020-08-04
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Depression, Anxiety, And Neurodegener App 20190275030 - Berg; James	2019-09-12
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Agitation In Dementia App 20190262332 - SIFFERT; Joao ; et al.	2019-08-29
Methods For The Synthesis Of Deuterated Dextromethorphan App 20190241525 - Johnson; Matt ; et al.	2019-08-08
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20190201391 - YAKATAN; Gerald ; et al.	2019-07-04
Pharmaceutical Compositions Comprising A Dextromethorphan Compound And Quinidine For The Treatment Of Agitation In Dementia App 20190111047 - SIFFERT; Joao	2019-04-18
Enhancement Of Impaired Motor And Mental Functions, Using Dextromethorphan And Oxidase Enzyme Inhibitor App 20190060306 - SMITH; Richard A.	2019-02-28
Enhancement Of Impaired Motor And Mental Functions, Using Dextromethorphan And Oxidase Enzyme Inhibitor App 20190054079 - Smith; Richard A.	2019-02-21
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20180098984 - YAKATAN; Gerald ; et al.	2018-04-12
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Depression, Anxiety, And Neurodegenerative Disorders App 20180008597 - Berg; James	2018-01-11
Enhancement Of Impaired Motor And Mental Functions, Using Dextromethorphan And Oxidase Enzyme Inhibitor App 20170354652 - SMITH; Richard A.	2017-12-14
Enhancement Of Impaired Motor And Mental Functions, Using Dextromethorphan And Oxidase Enzyme Inhibitor App 20170348301 - Smith; Richard A.	2017-12-07
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Agitation In Dementia App 20170333423 - SIFFERT; Joao ; et al.	2017-11-23
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20160287576 - Yakatan; Gerald ; et al.	2016-10-06
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Agitation In Dementia App 20160143901 - SIFFERT; Joao ; et al.	2016-05-26
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Depression, Anxiety, And Neurodegenerative Disorders App 20160008353 - Berg; James	2016-01-14
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20150209347 - Yakatan; Gerald ; et al.	2015-07-30
Method Of Reducing Cns And Gastrointestinal Side Affects Associated With Long-term, Dextromethorphan/low-dose Quinidine Combination Therapy App 20140315941 - Flesher; Gregory J. ; et al.	2014-10-23
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20140288114 - Yakatan; Gerald ; et al.	2014-09-25
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20140045880 - Yakatan; Gerald ; et al.	2014-02-13
Method Of Reducing Cns And Gastrointestinal Side Affects Associated With Long-term, Dextromethorphan/low-dose Quinidine Combination Therapy App 20130190346 - Flesher; Gregory J. ; et al.	2013-07-25
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Depression, Anxiety, And Neurodegenerative Disorders App 20130137714 - Berg; James	2013-05-30
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20130072517 - YAKATAN; Gerald ; et al.	2013-03-21
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders Grant 8,227,484 - Yakatan , et al. July 24, 2	2012-07-24
Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders App 20120165363 - YAKATAN; Gerald ; et al.	2012-06-28
Method Of Reducing Cns And Gastrointestinal Side Affects Associated With Long-term Dextromethorphan/low-dose Quinidine Combination Therapy App 20110212987 - Flesher; Gregory J. ; et al.	2011-09-01
Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Depression, Anxiety, and Neurodegenerative Disorders App 20110021552 - Berg; James	2011-01-27
Pharmaceutical Compositions Comprising Dextromethorphan And Quinidine For The Treatment Of Neurological Disorders App 20100137352 - YAKATAN; Gerald ; et al.	2010-06-03
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders Grant 7,659,282 - Yakatan , et al. February 9, 2	2010-02-09

Company Registrations

NCAGE Code	479A4	AVANIR PHARMACEUTICALS, INC.
CAGE Code	479A4	AVANIR PHARMACEUTICALS, INC.
S.A.M. Registration	479A4 [198413080]	AVANIR PHARMACEUTICALS, INC.
DUNS	198413080	Avanir Pharmaceuticals, Inc.
SEC	0000858803	AVANIR PHARMACEUTICALS, INC. of DELAWARE

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.